{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:16:08Z","timestamp":1790403368735,"version":"4.1.0"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0227128","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T13:37:53Z","timestamp":1578404273000},"page":"e0227128","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["What drugs modify the risk of iatrogenic impulse-control disorders in Parkinson\u2019s disease? A preliminary pharmacoepidemiologic study"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-8841","authenticated-orcid":true,"given":"Nakyung","family":"Jeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bortolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,1,7]]},"reference":[{"issue":"5","key":"pone.0227128.ref001","first-page":"589","article-title":"Impulse control disorders in Parkinson disease: A cross-sectional study of 3090 patients","volume":"67","author":"D Weintraub","journal-title":"Arch Neurol"},{"issue":"MAY","key":"pone.0227128.ref002","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3389\/fneur.2018.00330","article-title":"Impulse-control disorders in Parkinson\u2019s Disease: A meta-analysis and review of case-control studies","volume":"9","author":"H Molde","year":"2018","journal-title":"Front Neurol"},{"issue":"7","key":"pone.0227128.ref003","first-page":"1044","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson Disease: A 4-year randomized controlled trial","volume":"61","author":"RG Holloway","year":"2004","journal-title":"Arch Neurol"},{"issue":"1","key":"pone.0227128.ref004","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/mds.870130112","article-title":"Ropinirole versus bromocriptine in the treatment of early Parkinson\u2019s disease: A 6-month interim report of a 3-year study","volume":"13","author":"AD Korczyn","year":"1998","journal-title":"Mov Disord"},{"issue":"PG-S196-S197","key":"pone.0227128.ref005","first-page":"S196","article-title":"Assocation between impulse control disorders and the use of dopamine agonists","volume":"20","author":"KE Weddle","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"PG-40","key":"pone.0227128.ref006","first-page":"40","article-title":"Impulsive control disorders associated with dopamine agonists drugs: Analysis of cases reported in the European pharmacovigilance database (eudravigilance)","volume":"119","author":"C Aguirre","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"12","key":"pone.0227128.ref007","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","article-title":"Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs","volume":"174","author":"TJ Moore","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"8","key":"pone.0227128.ref008","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00702-018-1870-8","article-title":"Impulse control disorders in Parkinson\u2019s disease","volume":"125","author":"A Marques","year":"2018","journal-title":"J Neural Transm"},{"issue":"1","key":"pone.0227128.ref009","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","article-title":"Dopamine Agonists and Impulse Control Disorders: A Complex Association","volume":"41","author":"M Grall-Bronnec","year":"2018","journal-title":"Drug Saf"},{"issue":"8","key":"pone.0227128.ref010","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40266-013-0090-z","article-title":"Dopamine Agonist Withdrawal Syndrome: Implications for Patient Care","volume":"30","author":"MJ Nirenberg","year":"2013","journal-title":"Drugs Aging"},{"key":"pone.0227128.ref011","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/S1353-8020(11)70026-8","article-title":"Impulse control disorders in Parkinson\u2019s disease","volume":"18","author":"D Vilas","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"pone.0227128.ref012","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4088\/JCP.v63n0606","article-title":"A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling","volume":"63","author":"SW Kim","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"pone.0227128.ref013","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00004850-200607000-00002","article-title":"Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation","volume":"21","author":"JE Grant","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"pone.0227128.ref014","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4088\/JCP.08m04150","article-title":"A Double-Blind, Randomized, Placebo-Controlled Trial of Fluoxetine in Patients With Intermittent Explosive Disorder","volume":"70","author":"EF Coccaro","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"pone.0227128.ref015","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/JCP.0b013e318166c4bf","article-title":"Efficacy of Quetiapine for Impulsivity and Affective Symptoms in Borderline Personality Disorder","volume":"28","author":"F Van den Eynde","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"pone.0227128.ref016","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.pbb.2007.12.025","article-title":"A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers","volume":"89","author":"T Fong","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"pone.0227128.ref017","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/WNF.0000000000000276","article-title":"Treatment of Intermittent Explosive Disorder With Carbamazepine","volume":"41","author":"F Coskun","year":"2018","journal-title":"Clin Neuropharmacol"},{"issue":"7","key":"pone.0227128.ref018","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4088\/JCP.v63n0704","article-title":"Lithium and valproate treatment of pathological gambling: a randomized single-blind study","volume":"63","author":"S Pallanti","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"pone.0227128.ref019","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/WNL.0000000000000729","article-title":"Naltrexone for impulse control disorders in Parkinson disease","volume":"83","author":"K Papay","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"pone.0227128.ref020","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ajp.163.2.303","article-title":"Multicenter Investigation of the Opioid Antagonist Nalmefene in the Treatment of Pathological Gambling","volume":"163","author":"JE Grant","year":"2006","journal-title":"Am J Psychiatry"},{"key":"pone.0227128.ref021","article-title":"Targeting the Glutamatergic System to Treat Pathological Gambling: Current Evidence and Future Perspectives","author":"M Pettorruso","year":"2014","journal-title":"Biomed Res Int"},{"issue":"6","key":"pone.0227128.ref022","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.biopsych.2006.11.021","article-title":"N-Acetyl Cysteine, a Glutamate-Modulating Agent, in the Treatment of Pathological Gambling: A Pilot Study","volume":"62","author":"JE Grant","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"3","key":"pone.0227128.ref023","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1212\/01.WNL.0000076478.45005.EC","article-title":"Pathological gambling associated with dopamine agonist therapy in Parkinson\u2019s disease","volume":"61","author":"E Driver-Dunckley","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"pone.0227128.ref024","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ana.22029","article-title":"Pathological gambling in Parkinson disease is reduced by amantadine","volume":"68","author":"A Thomas","year":"2010","journal-title":"Ann Neurol"},{"issue":"6","key":"pone.0227128.ref025","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/aje\/kwk052","article-title":"Relaxing the Rule of Ten Events per Variable in Logistic and Cox Regression","volume":"165","author":"E Vittinghoff","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"4","key":"pone.0227128.ref026","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1212\/CPJ.0b013e318278be9b","article-title":"Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease","volume":"2","author":"HD Weiss","year":"2012","journal-title":"Neurol Clin Pract"},{"issue":"4","key":"pone.0227128.ref027","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0010-440X(96)90001-2","article-title":"Are impulse-control disorders related to bipolar disorder?","volume":"37","author":"SL McElroy","year":"1996","journal-title":"Compr Psychiatry"},{"issue":"3","key":"pone.0227128.ref028","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1017\/S1092852915000206","article-title":"Impulsivity and aggression in schizophrenia: a neural circuitry perspective with implications for treatment","volume":"20","author":"MJ Hoptman","year":"2015","journal-title":"CNS Spectr"},{"issue":"3","key":"pone.0227128.ref029","doi-asserted-by":"crossref","first-page":"CR182","DOI":"10.12659\/MSM.882523","article-title":"Aggressive and impulsive behavior in Alzheimer\u2019s disease and progression of dementia","volume":"18","author":"L Bidzan","year":"2012","journal-title":"Med Sci Monit"},{"issue":"5","key":"pone.0227128.ref030","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00005053-200205000-00007","article-title":"Impulse control disorders and depression","volume":"190","author":"M Lejoyeux","year":"2002","journal-title":"J Nerv Ment Dis"},{"issue":"6","key":"pone.0227128.ref031","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.22164","article-title":"Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study","volume":"68","author":"D Weintraub","year":"2010","journal-title":"Ann Neurol"},{"key":"pone.0227128.ref032","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/mds.23964","article-title":"Multiple impulse control disorders developing in Parkinson\u2019s disease after initiation of amantadine [Internet]","volume":"27","author":"RA Walsh","year":"2012","journal-title":"Movement Disorders"},{"issue":"3","key":"pone.0227128.ref033","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1176\/jnp.2006.18.3.377","article-title":"Escitalopram for Major Depression in Parkinson\u2019s Disease: An Open-Label, Flexible-Dosage Study","volume":"18","author":"D Weintraub","year":"2014","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"3","key":"pone.0227128.ref034","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4088\/JCP.v69n0316","article-title":"Escitalopram in the treatment of impulsive-compulsive internet usage disorder: An open-label trial followed by a double-blind discontinuation phase","volume":"69","author":"B Dell\u2019Osso","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"pone.0227128.ref035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4088\/JCP.v63n0109","article-title":"An open-label study of citalopram in the treatment of pathological gambling","volume":"63","author":"M Zimmerman","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"pone.0227128.ref036","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neuropharm.2016.11.014","article-title":"Pramipexole enhances disadvantageous decision-making: Lack of relation to changes in phasic dopamine release","volume":"114","author":"R Pes","year":"2017","journal-title":"Neuropharmacology"},{"issue":"4","key":"pone.0227128.ref037","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/syn.21805","article-title":"Parkinson\u2019s disease treatment may cause impulse-control disorder via dopamine D3 receptors","volume":"69","author":"P Seeman","year":"2015","journal-title":"Synapse"},{"issue":"4","key":"pone.0227128.ref038","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","article-title":"A review of uses of health care utilization databases for epidemiologic research on therapeutics","volume":"58","author":"S Schneeweiss","year":"2005","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"pone.0227128.ref039","first-page":"141","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson\u2019s disease","volume":"75","author":"A Thomas","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"pone.0227128.ref040","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/mds.27181","article-title":"Impulse control disorders in advanced Parkinson\u2019s disease with dyskinesia: The ALTHEA study","volume":"32","author":"R Biundo","year":"2017","journal-title":"Mov Disord"},{"key":"pone.0227128.ref041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2011.00001","article-title":"Impulse control disorders: updated review of clinical characteristics and pharmacological management","volume":"2","author":"L Schreiber","year":"2011","journal-title":"Front psychiatry"},{"issue":"4","key":"pone.0227128.ref042","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11910-001-0085-8","article-title":"Parkinson\u2019s disease: The treatment of drug-induced hallucinations and psychosis","volume":"1","author":"ES Molho","year":"2001","journal-title":"Curr Neurol Neurosci Rep"},{"key":"pone.0227128.ref043","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0306-4530(02)00111-7","article-title":"Atypical antipsychotics in the EPS-vulnerable patient","volume":"28","author":"JH Friedman","year":"2003","journal-title":"Psychoneuroendocrinology"},{"issue":"S3","key":"pone.0227128.ref044","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","article-title":"The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson\u2019s disease","volume":"26","author":"K Seppi","year":"2011","journal-title":"Mov Disord"},{"issue":"3","key":"pone.0227128.ref045","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1124\/jpet.105.092155","article-title":"Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the clozapine metabolite N-desmethylclozapine as a D2\/D3 partial agonist","volume":"315","author":"ES Burstein","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20133","key":"pone.0227128.ref046","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2011.05.005","article-title":"Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO","volume":"131","author":"R Mizrahi","year":"2011","journal-title":"Schizophr Res"},{"issue":"Suppl","key":"pone.0227128.ref047","first-page":"5","article-title":"Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity","volume":"55","author":"JE Leysen","year":"1994","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"pone.0227128.ref048","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200326090-00004","article-title":"Treatment of psychosis in Parkinson\u2019s disease","volume":"26","author":"HH Fernandez","year":"2003","journal-title":"Drug Saf"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0227128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T13:38:45Z","timestamp":1578404325000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0227128"}},"subtitle":[],"editor":[{"given":"Vincenzo","family":"De Luca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,7]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0227128","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,7]]}}}